Commentary · 21 Feb 2026
Conference abstractPublished 17 Jul 2017
Blocking WNT5A-interleukin-6-loop as an effective strategy to impair the invasive migration of BRAFinhibitor (BRAFi) resistant melanoma cells
Lund University, Sweden Skane University Hospital, Sweden All India Institute of Medical Sciences, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Metastasis is a major issue in melanoma patients with relapsing tumor resulted from acquired therapy resistance. A complete understanding on the metastatic regulators in targeted therapy-sensitive/resistant malignant melanoma and development of therapeutic molecules against these regulators will serve a crucial role in the treatment strategy for this deadly disease. The key metastatic regulators, WNT5A and interleukin-6 (IL-6) have been shown to induce melanoma progression. In the present study, we hypothesized that up-regulation of WNT5A-IL-6 feedback loop is associated with the acquired-resistance towards BRAFtargeted therapies and therefore might serve as a potential therapeutic target. We established three PLX4032-resistant melanoma cell lines with elevated IC50 for PLX4032 and ERK activity, compared with their respective parental cells. We observed increased expression of WNT5A and IL-6 along with parallel elevation in cell migration and invasion of PLX4032-resistant cells. Furthermore, we demonstrated that dual inhibition of WNT5A and IL-6 signaling (by Box5 and IL-6 neutralizing antibody) effectively impaired the migration and invasion of PLX4032-resistant cells. Overall, our results suggested that the elevated WNT5A and IL-6 levels in PLX4032-resistant melanoma cells fuels up the WNT5A-IL-6-loop thereby increasing cell migration and invasion, and combined inhibition of WNT5A and IL-6 could serve as a potential therapeutic strategy for BRAFi-resistant melanomas.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Purusottam Mohapatra”
- BylineArticles whose byline prints “Chandra P Prasad”
- BylineArticles whose byline prints “Gunilla Jonsson”
- BylineArticles whose byline prints “Farnaz Moradi”
- BylineArticles whose byline prints “Tommy Andersson”
